Multiple myeloma (MM) is a very heterogeneous disease, related in part to numerous chromosomal abnormalities. 1 We and others have shown that plasma cells of patients with t(11;14)(q13;q32) (representing approximately 15% of the patients with MM 1 ) were mature, with a small nucleus, clumped chromatic and reduced cytoplasm. 2, 3 Moreover, we have also described a strong association between both small mature plasma cell morphology, t(11;14) and CD20 expression. 4 Other data had previously suggested that the CD20 phenotype was associated with mature plasma cell morphology. 5 In the subset of patients with MM-expressing CD20, rituximab (anti-CD20 chimeric monoclonal antibody) could target the antigen and could have a clinical impact. Until now, only two phase II trial have been reported to determine the activity of rituximab in MM patients, with 1 patient out of 19 experiencing a partial response after therapy in the first one, 6 and no response in a cohort of 10 patients with pretreated advanced MM in the second one. 7 Nevertheless, in theses two series, patients were not selected according to the level of CD20 expression on plasma cells, and the majority of the patients were not expressing this phenotype at the time of therapy.
Thus, we conducted a prospective phase II trial of four weekly i.v. infusions of 375 mg/m 2 rituximab (Mabthéra, Roche pharmaceuticals, Neuilly, France) in patients with MM expressing CD20 on at least 33% of tumor cells. This study was approved by the Local Institutional Ethics Committee of the University of Nantes, was approved and registered by the French Agency for Health Security (Agence Française de Sécurité Sanitaire et des Produits de Santé: AFSSAPS). All patients gave written informed consent.
From July 2004 to February 2006, 14 consecutive patients: nine males and five females, median age 65 years (range ¼ 44-77 years) with either stage I MM never pre-treated (n ¼ 7) or stage III MM in relapse or refractory after a median of two lines of therapy (n ¼ 7) were treated. Immunophenotype using flow cytometry as previously described 4 revealed that all patients had CD20 positive MM with a median of 75% of the tumor cells were expressing CD20 (range ¼ 33-100%) at the onset of therapy. Rituximab was well tolerated. Responses were evaluated in each case 3 months after therapy according to Bladé criteria, 8 At the reference date of September 1, 2006, a single patient experienced a minor response, ongoing 18 months after rituximab therapy. This patient had previously relapsed 8 months after a double autologous stem cell transplantation. At the time of rituximab therapy, 100% of its plasma cells were expressing CD20; and 3 months after treatment, bone marrow examination showed 0.6% of plasma cells, none of them expressing CD20. Five patients (one with relapsed MM and four with stage I MM) experienced stable disease, ongoing for 3, 4, 4, 11 and 12 months, respectively. Three patients with stage I MM had stable disease but subsequently progressed 10, 11 and 15 months after therapy, respectively. The last five patients with relapsed MM did not respond to anti-CD20 therapy, despite partial clearance of CD20 þ plasma cells in the bone marrow in two cases. Conversely in the three latter cases, the percentage of CD20 þ plasma cells did not decrease despite rituximab therapy. Several factors have been described to explain resistance against rituximab in a variety of B-cell malignancies such as the level of CD20 expression, dissociated action of complementdependent cytotoxicity and antibody-dependant cellular cytotoxicity, 9 polymorphism in FcgammaRIIIA receptor and may be inadequate dose schedule. These mechanisms could explain the marginal activity of rituximab as single-agent in CD20 þ MM.
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This study was supported by Roche Pharmaceuticals, Neuillysur-Seine, France. In 2002, a t(4;22)(q12;q11) translocation fusing BCR to plateletderived growth factor receptor-alpha (PDGFRA) was first reported in two patients with Philadelphia chromosomenegative (Ph-neg) chronic myelogenous leukemia (CML). 1 Owing to the lack of imatinib, these patients underwent allogeneic stem cell transplantation. More recently, the same translocation was observed in two other patients with Ph-neg CML. Besides the inhibition of the aberrant BCR/ABL tyrosine kinase imatinib also affects other tyrosine kinases such as c-kit and the PDGFRs. Therefore, these patients received imatinib and achieved a hematologic and cytogenetic remission.
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Here, we report on a third patient with a t(4;22)(q12;q11) who is in hematological, cytogenetic and molecular long-term remission following treatment with imatinib at a dose of 100 mg/day.
In 2004, a 35-year-old male with an unremarkable medical report presented at our outpatient unit complaining about night sweat, loss of appetite and loss of weight of 6 kg. He had developed these symptoms during the last 2 months. He also suffered from nose, gum and petechial skin bleeding. He was a worker in a leather tannery having been exposed to varnish, colors and aromatic acids. For the last 2 years, before the onset of the symptoms, he worked as a truck driver.
He received ceterizin, magnesium and zinc tablets as well as xylometazolin nose spray for several years because of allergic symptoms related to the respiratory system without any side effects. His father died of cancer of the bladder and prostate, and his mother has meningeoma. He has six healthy siblings (three sisters and three brothers) of whom one sister is HLA identical. Physical examination showed splenomegaly without peripheral lymphadenopathy. This finding was confirmed by sonographical examination. The white blood cell count was elevated with a concentration of 58 000/ml, whereas a left shift in the differential blood count was noted. The hemoglobin level was 12.8 g/dl and the platelet count was 140 Â 10 3 /ml. An increase in LDH level (570 IU/l) was the only remarkable finding with regard to the serum biochemistry. The coagulation parameters were normal. The findings of the histological and cytomorphological bone marrow examination were compatible with a CML in chronic phase. Still, the results of a nested and multiplex RT-PCR performed were negative for BCR/ABL. Cytogenetic analyses were performed on the patient's bone marrow and peripheral blood and 22 metaphases were examined according to the ISCN 1995 guidelines. The analysis showed no Philadelphia chromosome but a translocation t(4;22)(q12;q11) in 18-22 metaphases. The translocation was further investigated by fluorescence in situ hybridization (FISH) using a probe mix consisting of a BAC probe (RP11-545H22, distal of PDGFRA) with the BCR-ABL Vysis probe. Nearly fused signals on the derivative chromosome 22 indicated a fusion between the genes PDGFRA and BCR. With interphase analysis we could show that 70-80% of the cells in the bone marrow harbor this translocation. To confirm the formation of a BCR/ PDGFRA fusion gene, FISH analyses with probes around the PDGFRA gene region were performed. A mixture of the probes RP11-571I18 (red, proximal of PDGFRA) and RP11-58C6 (green, covers the PDGFRA gene) was used to demonstrate the direct participation of PDGFRA. The BAC probe (green, RP11-58C6) containing the PDGFRA gene hybridizes to the derivative chromosomes 4 and 22 demonstrating a disruption of the gene (Figure 1 ).
